Beta test rollout. This site is in community QA — please send feature requests, bug reports and data corrections on the Feedback page or on GitHub.

Home
    Disclaimer
    PMA molecular structure

    PMA Stats & Data

    4-ma 4-methoxyamphetamine
    PubChem
    MW165.23
    FormulaC10H15NO
    LogP1.8
    IUPAC1-(4-methoxyphenyl)propan-2-amine
    SMILESCC(CC1=CC=C(C=C1)OC)N
    InChIKeyNEGYEDYHPHMHGK-UHFFFAOYSA-N
    Chemical Class Substituted amphetamine
    Psychoactive Class Psychedelic / Stimulant

    Pharmacology

    DrugBank
    State Solid

    Mechanism of Action

    4-Methoxyamphetamine is a seratogenic drug of the amphetamine class. The drug acts as a potent and selective serotonin releasing agent. It binds to alpha receptors to mediate these effects.

    Receptor Profile

    Receptor Actions

    Inhibitors
    Monoamine oxidase-A inhibitor (reversible)
    Other
    Selective serotonin releasing agent (SSRA)
    Weak dopamine and norepinephrine effects

    Toxicity

    PsychonautWiki

    PMA and its relative PMMA can be considered extremely toxic when compared to other substances such as Methamphetamine or MDMA . Ingestion of PMA has been associated with severe tachycardia (abnormally high heart rate), seizures, dehydration, hyperthermia, and death. PMA has a relatively slow onset, causing many users to redose which causes excess toxicity. It is strongly recommended that one use harm reduction practices when using this substance.

    Effect Profile

    Curated + 8 Reports
    Psychedelic 4.6

    Moderate visuals with mild auditory effects and body load, low headspace

    Visual Intensity×3
    7
    Headspace Depth×3
    2
    Auditory Effects×1
    4
    Body Load / Somatic Effects×1
    4
    Stimulant 3.8

    Moderate stimulation with strong anxiety/jitters, low euphoria and focus

    Stimulation / Energy×3
    6
    Euphoria / Mood Lift×2
    3
    Focus / Productivity×2
    2
    Anxiety / Jitters×1
    8

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown in humans; effects commonly persist 6–12+ hours and can be prolonged by delayed onset and potential MAOI-like activity.
    Addiction Potential
    Low to moderate for compulsive redosing; dependence uncommon, but binge patterns and psychological compulsion can occur with stimulants.

    Tolerance Decay

    Full tolerance 1d Half tolerance 7d Baseline ~14d

    Data on PMA-specific tolerance are scarce; pattern approximated from amphetamine-like stimulants with serotonergic activity. Anecdotal reports suggest rapid acute tolerance during binges and partial cross-tolerance with MDMA-class agents.

    Cross-Tolerances

    MDMA
    MDA
    other substituted amphetamines

    Experience Report Analysis

    Erowid
    17 Reports
    8 Single-substance
    2000–2009 Date Range
    1 With Age Data
    4 Effects Detected

    Demographics

    Gender Distribution

    Too few reports for a chart: gender is known from 17 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?

    • Female 4 of 17
    • Male 12 of 17
    • Not Specified 1 of 17

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 8 experience reports (8 single-substance Erowid)

    8 Reports
    4 Effects Detected
    1 Positive
    2 Adverse
    1 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

    Too few reports for bars: these effects come from 8 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

    Positive Effects 1

    Euphoria 3 of 8 70%

    Adverse Effects 2

    Nausea 3 of 8 70%
    Anxiety 3 of 8 70%
    Show 1 neutral or unclassified mention
    Hospital 4 of 8

    Also reported in combinations. In the 9 PMA reports where another drug was taken too, 4 mention hospital, emergency services or an overdose, 0 a seizure and 2 psychosis (too few reports for percentages). In the 8 single-substance reports: 4, 0 and 0. These are not in the figures above: they cannot be put down to PMA alone, and a mention is not always something that happened to the writer.

    Common Combinations

    Most co-occurring substances, as a share of all 17 reports filed under PMA

    Too few reports for bars: these combinations come from 17 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

    • THC 4 of 17

    Form / Preparation

    Most common forms and preparations, as a share of the 8 reports that give one

    Too few reports for bars: these forms come from 8 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

    • Pill / Tablet 7 of 8

    Redose Patterns

    Redosing behavior across 10 reports

    0 of 10 Redosed
    1.0 Avg Doses

    Too few reports for a chart: redosing is known from 10 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?

    • Single dose 10 of 10
    • Redosed 0 of 10

    Legal Status

    Controlled internationally under the UN Convention on Psychotropic Substances 1971.
    Country Status Notes
    Australia PMA is considered a Schedule 9 prohibited substance in Australia under the Poisons Standard (October 2015). A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.
    Austria PMA is illegal to possess, produce and sell under the SMG (Suchtmittelgesetz Österreich) |
    Brazil Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.
    Canada PMA is a Schedule I substance.
    Finland Substance is scheduled in decree of the government on amending the government decree on substances, preparations and plants considered to be narcotic drugs.
    Germany PMA is part of the Appendix 1 of the Betäubungsmittelgesetz. Therefore, owning and distribution of PMA is illegal.
    Netherlands On 13 June 2012 Edith Schippers, Dutch Minister of Health, Welfare and Sport, revoked the legality of PMA in the Netherlands after five deaths were reported in that year.
    Russia PMA is classed as a Schedule I substance.
    Switzerland PMA is a controlled substance specifically named under Verzeichnis D.
    United Kingdom PMA is a Class A drug in the UK.
    United States PMA is classified as a Schedule I hallucinogen under the Controlled Substances Act in the United States.

    Harm Reduction

    drugs.wiki

    Extremely narrow therapeutic index: the gap between a ‘common’ dose and life-threatening toxicity is small. PMA is frequently mis-sold as MDMA in pressed pills or powders, but it has slower onset (often >60 minutes) and less euphoria, prompting risky redosing that has been implicated in clusters of fatalities. Expect marked hyperthermia and hypertension risk; avoid hot environments, prolonged dancing, and strenuous activity. If effects are unexpectedly delayed or atypical for MDMA, do not redose and seek a cool, quiet space. Hydrate with small sips of isotonic fluids (~300 mL/hour) and avoid overhydration. Reagent testing: PMA typically shows no reaction with Marquis/Mecke; PMMA may show a blue Simon’s reaction without MDMA-like Marquis/Mecke changes. Absence of the expected MDMA reaction is a red flag—only lab drug checking (e.g., GC/MS) can confirm composition. Strongly avoid combinations with serotonergic agents (SSRIs, MAOIs, tramadol, dextromethorphan, triptans) and with other stimulants or MDMA, due to serotonin syndrome and hyperthermia risk. Seek emergency help for high temperature, confusion/agitation, severe headache, chest pain, or persistent vomiting. Given its poor safety profile and repeated association with deaths, routine recreational use is not advised.

    ← Back to PMA